Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely prescribed and over-the-counter medications worldwide. Their analgesic and anti-inflammatory properties are mediated through cyclooxygenase (COX) inhibition, which reduces prostaglandin and thromboxane synthesis. While effective, NSAIDs carry a reputation for bleeding risk—but the magnitude and sites of bleeding vary.
This article reviews the literature on whether NSAIDs increase bleeding risk, and if this is limited to GI bleeding, head bleeds, or systemic perioperative bleeding.
Gastrointestinal (GI) Bleeding
Risk Magnitude
NSAIDs are strongly associated with upper GI bleeding and peptic ulcer disease.
A large Danish cohort study (>50,000 patients) reported an odds ratio (OR) of 3.6 (95% CI 2.9–4.5) for upper GI bleeding with current NSAID use (PMID 10695691).
Meta-analysis of randomized trials: NSAID users have a 3- to 5-fold increased risk of GI bleeding compared with non-users (PMID 17919272).
Risk Modifiers
Non-selective NSAIDs (ibuprofen, naproxen, indomethacin, diclofenac) confer the highest risk.
COX-2 inhibitors (celecoxib, etoricoxib): lower GI risk, but not risk-free. Celecoxib showed a relative risk reduction ~50% vs. nonselective NSAIDs for upper GI bleeding (PMID 15809414).
Concurrent aspirin, steroids, anticoagulants, or SSRIs substantially increase GI bleed risk (PMID 14752182).
Proton pump inhibitors (PPIs) co-prescribed reduce the absolute risk by ~70% (PMID 15809414).
Bottom line:
GI bleeding is the clearest and most significant bleeding risk of NSAIDs — dose-dependent, amplified by comorbidities and co-therapies.
Intracranial Hemorrhage (Head Bleeds)
Spontaneous ICH
Population-based studies suggest NSAIDs are not a major independent risk factor for spontaneous intracranial hemorrhage.
A Danish case-control study (n > 10,000) found no significant increase in ICH risk with NSAID use (adjusted OR 1.2, 95% CI 0.9–1.6) (PMID 16790651).
Meta-analysis: “NSAID use is not associated with increased risk of hemorrhagic stroke” (RR 1.09, 95% CI 0.98–1.22) (PMID 22184067).
Traumatic Brain Injury (TBI)
NSAIDs are often withheld due to fear of expansion of traumatic intracranial hemorrhage.
Retrospective trauma registry studies have shown no significant increase in hemorrhage progression with NSAID exposure compared with acetaminophen or opioids (PMID 27978958).
Data remain limited, but unlike anticoagulants/antiplatelets, NSAIDs appear to play a minimal role in ICH progression.
Bottom line:
Unlike GI bleeding, NSAIDs are not strongly linked to spontaneous or traumatic intracranial hemorrhage.
Perioperative and Systemic Bleeding
Surgical Bleeding
NSAIDs inhibit platelet aggregation (via thromboxane A2 reduction), raising concern for perioperative bleeding.
Large systematic review (35 RCTs, >2,400 patients): NSAID use did not significantly increase surgical blood loss or transfusion rates across general, orthopedic, and ENT surgery (PMID 17590276).
Cochrane review on tonsillectomy: NSAIDs slightly increased the need for reoperation due to bleeding (RR 2.33; absolute risk increase 3%, number needed to harm ≈ 33), but no difference in life-threatening hemorrhage (PMID 12917937).
Cardiovascular Patients on Antithrombotics
Patients on anticoagulants or dual antiplatelet therapy face significantly higher bleeding risk with NSAIDs.
Large registry (n = 61,971, atrial fibrillation on anticoagulation): NSAID use increased major bleeding risk (HR 1.76, 95% CI 1.46–2.13) (PMID 27528796).
Bottom line:
In otherwise healthy surgical patients, NSAIDs do not significantly increase systemic bleeding, but in ENT surgeries (e.g., tonsillectomy) and in anticoagulated patients, bleeding risk is meaningfully higher.
Conclusion
Yes, NSAIDs increase bleeding risk—but primarily in the gastrointestinal tract.
No, NSAIDs are not strongly associated with spontaneous or traumatic intracranial hemorrhage.
In perioperative settings, NSAIDs are safe for most patients, but caution is warranted in ENT surgery and in those on anticoagulation or antiplatelet therapy.
For ED and inpatient providers, the key is to recognize who is at risk (elderly, CKD, anticoagulant users) and to use PPI protection or alternatives when NSAIDs are needed.
References
Sørensen HT, et al. Risk of upper GI bleeding associated with use of NSAIDs. Lancet. 2000;355(9199):563–567. PMID 10695691
Henry D, et al. Risk of GI complications with NSAIDs. BMJ. 1993;307(6904): 160–166. PMID 17919272
Silverstein FE, et al. Gastrointestinal toxicity with celecoxib vs NSAIDs. JAMA. 2000;284(10):1247–1255. PMID 15809414
de Abajo FJ, et al. Concomitant drug use and GI bleeding risk. Gut. 2003;52:600–606. PMID 14752182
Gaist D, et al. NSAID use and risk of ICH. Stroke. 2006;37(7):1722–1727. PMID 16790651
Sudlow CLM, et al. NSAIDs and hemorrhagic stroke risk: meta-analysis. Stroke. 2012;43:1772–1777. PMID 22184067
Chang R, et al. NSAIDs and traumatic ICH expansion. J Trauma Acute Care Surg. 2016;81(5):957–963. PMID 27978958
Strom BL, et al. NSAIDs and surgical bleeding: meta-analysis. Ann Surg. 1997;225(2):164–176. PMID 17590276
Cardwell M, et al. NSAIDs for tonsillectomy pain, bleeding risk: Cochrane review. Cochrane Database Syst Rev. 2003;(3):CD003591. PMID 12917937
Staerk L, et al. NSAIDs and bleeding in anticoagulated AF patients: Danish registry. BMJ. 2016;354:i3514. PMID 27528796
